DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
RISUTEGANIB
2
Protein
Investigational
Unknown
Unknown
Macular Degeneration
Unknown
RISUTEGANIB
×
Maximum Phase:
2
First Approval:
None
UNII:
123DNA66IA
Molecule Type:
Protein
Molecular Formula:
C22H39N9O11S
Molecular Weight:
637.67
AlogP:
-5.88
PSA:
336.53
HBD:
11.0
HBA:
#RotB:
17.0
Source:
CENTANAFADINE HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Attention Deficit Disorder with Hyperactivity
Unknown
CENTANAFADINE HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
265DN9X85W
Molecule Type:
Small molecule
Molecular Formula:
C15H16ClN
Molecular Weight:
245.75
AlogP:
2.7
PSA:
12.03
HBD:
1.0
HBA:
#RotB:
1.0
Source:
MVA85A
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
MVA85A
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DILPACIMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms
Unknown
DILPACIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
F27LAH6D5O
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ALT-2074
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ALT-2074
×
Maximum Phase:
2
First Approval:
None
UNII:
634U7OUR4R
Molecule Type:
Small molecule
Molecular Formula:
C10H13NSe
Molecular Weight:
226.18
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
GELDANAMYCIN
2
Small molecule
Investigational
Unknown
Unknown
Kidney Neoplasms; von Hippel-Lindau Disease
Unknown
GELDANAMYCIN
×
Maximum Phase:
2
First Approval:
None
UNII:
Z3K3VJ16KU
Molecule Type:
Small molecule
Molecular Formula:
C29H40N2O9
Molecular Weight:
560.64
AlogP:
2.41
PSA:
163.48
HBD:
3.0
HBA:
#RotB:
4.0
Source:
UPROSERTIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Breast Neoplasms; Leukemia, Myeloid, Acute; Melanoma; Multiple Myeloma; Uterine Cervical Neoplasms
Serine/threonine-protein kinase AKT inhibitor
UPROSERTIB
×
Maximum Phase:
2
First Approval:
None
UNII:
ZXM835LQ5E
Molecule Type:
Small molecule
Molecular Formula:
C18H16Cl2F2N4O2
Molecular Weight:
429.25
AlogP:
3.56
PSA:
86.08
HBD:
2.0
HBA:
#RotB:
6.0
Source:
ILEPATRIL
2
Small molecule
Investigational
Unknown
Unknown
Hypertension
Angiotensin-converting enzyme inhibitor
ILEPATRIL
×
Maximum Phase:
2
First Approval:
None
UNII:
5N1YAP5FCM
Molecule Type:
Small molecule
Molecular Formula:
C22H28N2O5S
Molecular Weight:
432.54
AlogP:
2.54
PSA:
103.78
HBD:
2.0
HBA:
#RotB:
5.0
Source:
ONALESPIB
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Prostatic Neoplasms, Castration-Resistant
Heat shock protein HSP90 inhibitor
ONALESPIB
×
Maximum Phase:
2
First Approval:
None
UNII:
Q7Y33N57ZZ
Molecule Type:
Small molecule
Molecular Formula:
C24H31N3O3
Molecular Weight:
409.53
AlogP:
3.12
PSA:
67.25
HBD:
2.0
HBA:
#RotB:
4.0
Source:
OCR-002
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
OCR-002
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AVE8134
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Peroxisome proliferator-activated receptor alpha agonist
AVE8134
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SELATOGREL
2
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Coronary Disease; Myocardial Infarction
Purinergic receptor P2Y12 antagonist
SELATOGREL
×
Maximum Phase:
2
First Approval:
None
UNII:
6DPK7O4PR7
Molecule Type:
Small molecule
Molecular Formula:
C28H39N6O8P
Molecular Weight:
618.63
AlogP:
1.73
PSA:
174.73
HBD:
3.0
HBA:
#RotB:
11.0
Source:
MAPATUMUMAB
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Multiple Myeloma
TRAIL receptor-1 agonist
MAPATUMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
WZ1025JPGR
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MAVOGLURANT
2
Small molecule
Investigational
Unknown
Unknown
Alcoholism; Alcohol Drinking; Gastroesophageal Reflux; Kidney Diseases; Liver Diseases; Chorea; Cocaine-Related Disorders; Fragile X Syndrome; Huntington Disease; Obsessive-Compulsive Disorder; Parkinson Disease
Metabotropic glutamate receptor 5 antagonist
MAVOGLURANT
×
Maximum Phase:
2
First Approval:
None
UNII:
GT0I9SV4F6
Molecule Type:
Small molecule
Molecular Formula:
C19H23NO3
Molecular Weight:
313.4
AlogP:
2.72
PSA:
49.77
HBD:
1.0
HBA:
#RotB:
0.0
Source:
TRIFOLIUM PRATENSE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
TRIFOLIUM PRATENSE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FORETINIB
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Lung Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Head and Neck Neoplasms; Neoplasms
Hepatocyte growth factor receptor inhibitor
FORETINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
81FH7VK1C4
Molecule Type:
Small molecule
Molecular Formula:
C34H34F2N4O6
Molecular Weight:
632.66
AlogP:
5.77
PSA:
111.25
HBD:
2.0
HBA:
#RotB:
12.0
Source:
ANTHRAX VACCINE ABSORBED
2
Unknown
Investigational
Unknown
Unknown
Anthrax
Unknown
ANTHRAX VACCINE ABSORBED
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RAMATROBAN
2
Small molecule
Investigational
Unknown
Unknown
Asthma
G protein-coupled receptor 44 antagonist
RAMATROBAN
×
Maximum Phase:
2
First Approval:
None
UNII:
P1ALI72U6C
Molecule Type:
Small molecule
Molecular Formula:
C21H21FN2O4S
Molecular Weight:
416.47
AlogP:
3.09
PSA:
88.4
HBD:
2.0
HBA:
#RotB:
6.0
Source:
SGS-742
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease
GABA-B receptor antagonist
SGS-742
×
Maximum Phase:
2
First Approval:
None
UNII:
GBZ5UC0RME
Molecule Type:
Small molecule
Molecular Formula:
C7H18NO2P
Molecular Weight:
179.2
AlogP:
1.41
PSA:
63.32
HBD:
2.0
HBA:
#RotB:
6.0
Source:
SENREBOTASE
2
Enzyme
Investigational
Unknown
Unknown
Neuralgia, Postherpetic; Urinary Bladder, Overactive
Unknown
SENREBOTASE
×
Maximum Phase:
2
First Approval:
None
UNII:
8SQP8A30GG
Molecule Type:
Enzyme
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SEPANTRONIUM BROMIDE
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Melanoma; Prostatic Neoplasms
Unknown
SEPANTRONIUM BROMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
7H5Q4J1CM5
Molecule Type:
Small molecule
Molecular Formula:
C20H19BrN4O3
Molecular Weight:
443.3
AlogP:
1.34
PSA:
77.96
HBD:
0.0
HBA:
#RotB:
5.0
Source:
VIDUPIPRANT
2
Small molecule
Investigational
Unknown
Unknown
Asthma
G protein-coupled receptor 44 antagonist
VIDUPIPRANT
×
Maximum Phase:
2
First Approval:
None
UNII:
61OTZ32XNC
Molecule Type:
Small molecule
Molecular Formula:
C28H27Cl2FN2O6S
Molecular Weight:
609.5
AlogP:
6.76
PSA:
121.8
HBD:
3.0
HBA:
#RotB:
9.0
Source:
FB-825
2
Unknown
Investigational
Unknown
Unknown
Dermatitis, Atopic
Unknown
FB-825
×
Maximum Phase:
2
First Approval:
None
UNII:
YO4XL7781V
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ADELMIDROL
2
Small molecule
Investigational
Unknown
Unknown
Vaginitis
Unknown
ADELMIDROL
×
Maximum Phase:
2
First Approval:
None
UNII:
1BUC3685QU
Molecule Type:
Small molecule
Molecular Formula:
C13H26N2O4
Molecular Weight:
274.36
AlogP:
-0.07
PSA:
98.66
HBD:
4.0
HBA:
#RotB:
12.0
Source:
INCYCLINIDE
2
Small molecule
Investigational
Unknown
Unknown
Central Nervous System Neoplasms; Neoplasms
Unknown
INCYCLINIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
21G64WZQ4I
Molecule Type:
Small molecule
Molecular Formula:
C19H17NO7
Molecular Weight:
371.35
AlogP:
0.58
PSA:
158.15
HBD:
5.0
HBA:
#RotB:
1.0
Source:
SITAFLOXACIN
2
Small molecule
Investigational
Unknown
Unknown
Bacterial Infections
Bacterial DNA gyrase inhibitor
SITAFLOXACIN
×
Maximum Phase:
2
First Approval:
None
UNII:
45IP57B62B
Molecule Type:
Small molecule
Molecular Formula:
C19H18ClF2N3O3
Molecular Weight:
409.82
AlogP:
2.7
PSA:
88.56
HBD:
2.0
HBA:
#RotB:
3.0
Source:
VILOBELIMAB
2
Antibody
Investigational
Unknown
Unknown
Granulomatosis with Polyangiitis; Hidradenitis Suppurativa; Inflammation; Microscopic Polyangiitis; Pyoderma; Scleroderma, Systemic; Sepsis; Severe Acute Respiratory Syndrome; Shock, Septic
Complement C5 inhibitor
VILOBELIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FOSMANOGEPIX
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Candidemia; Mycoses
GPI-anchored wall transfer protein 1 inhibitor
FOSMANOGEPIX
×
Maximum Phase:
2
First Approval:
None
UNII:
1XQ871489P
Molecule Type:
Small molecule
Molecular Formula:
C22H21N4O6P
Molecular Weight:
468.41
AlogP:
2.21
PSA:
147.64
HBD:
2.0
HBA:
#RotB:
9.0
Source:
LY-2606368
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Neoplasms; Ovarian Neoplasms
Serine/threonine-protein kinase Chk1 inhibitor
LY-2606368
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FALLYPRIDE
2
Small molecule
Investigational
Unknown
Unknown
Obesity, Morbid; Obesity
Unknown
FALLYPRIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
G9FWZ369GX
Molecule Type:
Small molecule
Molecular Formula:
C20H29FN2O3
Molecular Weight:
364.46
AlogP:
2.99
PSA:
50.8
HBD:
1.0
HBA:
#RotB:
10.0
Source:
E-7016
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Melanoma
Unknown
E-7016
×
Maximum Phase:
2
First Approval:
None
UNII:
M8926C7ILX
Molecule Type:
Small molecule
Molecular Formula:
C20H19N3O3
Molecular Weight:
349.39
AlogP:
2.65
PSA:
78.45
HBD:
2.0
HBA:
#RotB:
2.0
Source:
ATOPAXAR
2
Small molecule
Investigational
Unknown
Unknown
Acute Coronary Syndrome; Coronary Disease
Proteinase-activated receptor 1 antagonist
ATOPAXAR
×
Maximum Phase:
2
First Approval:
None
UNII:
HTI275SD2D
Molecule Type:
Small molecule
Molecular Formula:
C29H38FN3O5
Molecular Weight:
527.64
AlogP:
4.79
PSA:
84.32
HBD:
1.0
HBA:
#RotB:
9.0
Source:
PERPHENAZINE 4-AMINOBUTYRATE
2
Small molecule
Investigational
Unknown
Unknown
Schizophrenia
Unknown
PERPHENAZINE 4-AMINOBUTYRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
K1WO7H97QZ
Molecule Type:
Small molecule
Molecular Formula:
C25H33ClN4O2S
Molecular Weight:
489.09
AlogP:
4.23
PSA:
62.04
HBD:
1.0
HBA:
#RotB:
10.0
Source:
ABX-464
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease; HIV Infections; Severe Acute Respiratory Syndrome
Cap binding complex modulator
ABX-464
×
Maximum Phase:
2
First Approval:
None
UNII:
26RU378B9V
Molecule Type:
Small molecule
Molecular Formula:
C16H10ClF3N2O
Molecular Weight:
338.72
AlogP:
5.53
PSA:
34.15
HBD:
1.0
HBA:
#RotB:
3.0
Source:
DKN-01
2
Unknown
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Biliary Tract Neoplasms
Dickkopf-related protein 1 inhibitor
DKN-01
×
Maximum Phase:
2
First Approval:
None
UNII:
RM898LZ4SI
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
161
162
163
164
165
166
167
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA